sc0151.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 9)
 
TREDEGAR CORPORATION
(Name of Issuer)
 
 
COMMON STOCK
(Title of class of securities)
 
 
894650 100
(CUSIP NUMBER)
 
 
John D. Gottwald
William M. Gottwald
Floyd D. Gottwald, Jr.
c/o John D. Gottwald
Westham Partners
9030 Stony Point Parkway, Suite 170
Richmond, Virginia 23235
Telephone No. 804-560-6961
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
 
Copy to:
Jay Clayton
Janet Geldzahler
Sullivan & Cromwell LLP
125 Broad Street
New York, New York 10004
Telephone No. 212-558-4000
 
October 4, 2013
(Date of Event which Requires Filing of this Statement)
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  o


 
 

 
 

CUSIP NO. 894650 100
13D
Page 2 of 11 Pages
 
 
1
NAMES OF REPORTING PERSONS
 
 
 
John D. Gottwald
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
 
(a)  T
 
(b)  £
3
SEC USE ONLY
 
 
 
 
4
SOURCE OF FUNDS*
 
 
 
PF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
 
£
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
 
USA
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
 
 
 
1,983,041
8
SHARED VOTING POWER
 
 
 
2,929,462
9
SOLE DISPOSITIVE POWER
 
 
 
1,983,041
10
SHARED DISPOSITIVE POWER
 
 
 
2,929,462
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
 
4,912,503
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
 
 
 
x
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
 
15.2%
14
TYPE OF REPORTING PERSON*
 
 
 
IN


*SEE INSTRUCTIONS BEFORE FILLING OUT*



 
 

 


CUSIP NO. 894650 100
13D
Page 3 of 11 Pages

 
1
NAMES OF REPORTING PERSONS
 
 
 
William M. Gottwald
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
 
(a)  T
 
(b)  £
3
SEC USE ONLY
 
 
 
 
4
SOURCE OF FUNDS*
 
 
 
PF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
 
£
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
 
USA
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
 
 
 
63,676
8
SHARED VOTING POWER
 
 
 
2,657,099
9
SOLE DISPOSITIVE POWER
 
 
 
63,676
10
SHARED DISPOSITIVE POWER
 
 
 
2,657,099
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
 
2,720,775
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
 
 
 
x
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
 
8.4%
14
TYPE OF REPORTING PERSON*
 
 
 
IN


*SEE INSTRUCTIONS BEFORE FILLING OUT*
 

 
 

 


CUSIP NO. 894650 100
13D
Page 4 of 11 Pages

 
1
NAMES OF REPORTING PERSONS
 
 
 
Floyd D. Gottwald, Jr.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
 
(a)  T
 
(b)  £
3
SEC USE ONLY
 
 
 
 
4
SOURCE OF FUNDS*
 
 
 
PF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
 
£
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
 
USA
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
 
 
 
2,265,395
8
SHARED VOTING POWER
 
 
 
123,965
9
SOLE DISPOSITIVE POWER
 
 
 
2,265,395
10
SHARED DISPOSITIVE POWER
 
 
 
123,965
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
 
2,389,360
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
 
 
 
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
 
7.4%
14
TYPE OF REPORTING PERSON*
 
 
 
IN


*SEE INSTRUCTIONS BEFORE FILLING OUT*

 
 
 

 

*   Amendment No. 9 amends and supplements Amendment Nos. 1 through 8 to the statement on Schedule 13D initially filed on August 15, 1989 with respect to shares of common stock (the “Common Stock”) of Tredegar Corporation (the “Issuer”), as well as the Schedule 13D filed by Floyd D. Gottwald, Jr. on January 21, 2009 (the “ Second Schedule 13D”).

Item 3.
Source and Amount of Funds or Other Consideration.

Since the filing of Amendment No. 8, none of John D. Gottwald, William M. Gottwald and Floyd D. Gottwald, Jr. has purchased additional shares of Common Stock except, in the case of John D. Gottwald and William M. Gottwald, acquisitions pursuant to quarterly awards under the Issuer’s director compensation program.

Item 4.
Purpose of the Transaction.

On October 4, 2013, John D. Gottwald and William M. Gottwald sent a letter, attached as Exhibit 2 hereto, to the Board of Directors of the Issuer asking the Board to advise them under the Issuers Amended and Restated Rights Agreement, should the Gottwalds determine to so proceed, whether the nomination of individuals to a slate of directors running on a platform to pursue strategic alternatives, including a possible sale of the Issuer, as well as implementing certain corporate governance initiatives, would cause the Gottwalds to “Beneficially Own” any Common Stock held by such nominees, in the absence of an agreement on how nominees would vote their shares. The foregoing is qualified in its entirety by Exhibit 2.
 
Item 5.
Interest in Securities of the Issuer.

(a) Amount Beneficially Owned: 7,371,736 shares 1/

Percentage of Class Owned: 22.8%

(b) Number of shares as to which such persons have:

 
(i)
sole power to vote or to direct the vote – 4,312,112

 
(ii)
shared power to vote or to direct the vote – 3,059,624

 
(iii)
sole power to dispose of or to direct the disposition of – 4,312,112

 
(iv)
shared power to dispose of or to direct the disposition of – 3,059,624

1/ This does not include 90,000 shares held by the John D. Gottwald Family Trust, the trustee of which is James Gottwald, the brother of John D. Gottwald and William M. Gottwald, or any shares held by the adult children of John D. Gottwald and William M. Gottwald who do not live with their fathers, which shares aggregate less than 1%. The filing of this statement shall not be construed as an admission that, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, Floyd D. Gottwald, Jr., John D. Gottwald and William M. Gottwald are the beneficial owners of the shares described in Items 5(b)(ii) and (iv). See Item 5(d) below.
 
 
 

 
Page 5 of 11 Pages


 
 

 


(c) Except as reported on Amendment No. 8 filed on September 6, 2013, there have been no transactions by John D. Gottwald, William M. Gottwald or Floyd D. Gottwald, Jr. in the past 60 days involving shares of the Issuer’s Common Stock, except that each of John D. Gottwald and William M. Gottwald received 543 shares on September 30, 2013 in director quarterly grants.
 
(d) Other persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, 3,059,624 of the shares described in Items 5(b)(ii) and (iv). However, none of any such person’s individual interest relates to more than five percent of the class of securities for which this Form is filed.
 
 
 
 
 
 
 
 
Page 6 of 11 Pages
 
 
 

 

 
 
Item 7.
Material to be Filed as Exhibits.
 
 
 
Exhibit 1
Agreement among Floyd D. Gottwald, Jr., John D. Gottwald and William M. Gottwald with respect to the filing of this Amendment No. 9 to the Schedule 13D.
     
  Exhibit 2 Letter dated October 4, 2013 to the Tredegar Board of Directors.
 





 


























Page 7 of 11 Pages


 
 

 


After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
 

Date:  October 4, 2013
 
/s/ John D. Gottwald
   
  John D. Gottwald
     
   
/s/ William M. Gottwald
   
  William M. Gottwald
     
   
/s/ Floyd D. Gottwald, Jr.
   
  Floyd D. Gottwald, Jr.



























Page 8 of 11 Pages



 
 

 

EXHIBIT INDEX
 

 
Exhibit 1
Agreement among Floyd D. Gottwald, Jr., John D. Gottwald and William M. Gottwald with respect to the filing of this Amendment No. 9 to the Schedule 13D. 
   
Exhibit 2
Letter dated October 4, 2013 to the Tredegar Board of Directors.


































Page 9 of 11 Pages
 

 


ex_99-1.htm
EXHIBIT 1
 
 
 
We, the undersigned, hereby express our agreement that the attached Amendment No. 9 is filed on behalf of each the undersigned.
 
 
 

Date: October 4, 2013
 
/s/ John D. Gottwald
   
John D. Gottwald
     
   
/s/ William M. Gottwald
   
William M. Gottwald
     
   
/s/ Floyd D. Gottwald, Jr.
   
Floyd D. Gottwald, Jr.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 10 of 11 Pages
 
 
 

ex_99-2.htm
EXHIBIT 2
 
October 4, 2013
 

 

 
Board of Directors of Tredegar Corporation
 
Dear Fellow Directors:
 
We are writing you with respect to the Amended and Restated Rights Agreement, or poison pill,  of Tredegar Corporation.  As you know, we have filed a Schedule 13D indicating that we may propose a slate of director nominees at Tredegar’s next annual meeting.  As we read it, under the terms of the Rights Agreement, if there is “any agreement, arrangement or understanding (whether or not in writing) with respect to any securities of the Company ... except pursuant to a revocable proxy….”, each party to the agreement becomes the “Beneficial Owner” of the shares owned by the other parties to the agreement. We note that under Section 29 of the Rights Agreement, the Board is charged with interpreting the provisions of the Rights Agreement.   Our question is simple—if we nominate individuals that own shares of Tredegar Common Stock, does the Board interpret that fact to cause us to become the Beneficial Owner of those shares or such nominees to be the Beneficial Owner of our shares?  If we determine to nominate directors, it would be on a platform that the nominees believe that the Board should consider Tredegar’s strategic alternatives, including a possible sale of Tredegar,  as well as implement certain corporate governance initiatives, but we would not be asking any nominee to make a commitment as to how they would vote their shares in the proxy contest.
 
If we follow the path of nominating a slate of directors, we want to select the most qualified persons to serve on that slate, those whose interests are most closely aligned with all shareholders.   Using the terms of a poison pill to disqualify individuals who own shares seems to us to be unwise as a matter of corporate governance and contradictory to the long standing precept that poison pills are not to be used to prevent shareholders from choosing a corporation’s directors—the Rights Agreement itself excludes from the definition of Beneficial Ownership shares as to which there is a right to vote as a result of a revocable proxy given in response to a public proxy solicitation.
 
We would appreciate a response to this question within the next two weeks.
 
Sincerely,
 
 
John D. Gottwald
 
William M. Gottwald
 

 
 
 
 
 
 
Page 11 of 11 Pages